BiotechTube

ZY19489 + Ferroquine (FQ) + Placebo

Phase 1Recruiting
0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Uncomplicated Malaria

Conditions

Uncomplicated Malaria, Asymptomatic Condition, Falciparum Malaria

Trial Timeline

Aug 30, 2024 → May 30, 2025

NCT ID
NCT05911828

About ZY19489 + Ferroquine (FQ) + Placebo

ZY19489 + Ferroquine (FQ) + Placebo is a phase 1 stage product being developed by Zydus Lifesciences for Uncomplicated Malaria. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05911828. Target conditions include Uncomplicated Malaria, Asymptomatic Condition, Falciparum Malaria.

What happened to similar drugs?

1 of 6 similar drugs in Uncomplicated Malaria were approved

Approved (1) Terminated (0) Active (5)
✅Co-artemetherNovartisApproved
🔄KLU156 + CoartemNovartisPhase 3
🔄Broncho-munal® + PlaceboSandoz GroupPhase 3
🔄Placebo of Phenazopyridine Hydrochloride Tables, USP 200 mg + Phenazopyridine Hydrochloride Tables, USP 200 mgAmneal PharmaceuticalsPhase 3
🔄solithromycin + ceftriaxone + azithromycinAllergy TherapeuticsPhase 3
🔄Sulopenem-Etzadroxil/Probenecid + CiprofloxacinIterum TherapeuticsPhase 3

Hype Score Breakdown

Clinical
6
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05911828Phase 1Recruiting

Competing Products

13 competing products in Uncomplicated Malaria

See all competitors
ProductCompanyStageHype Score
KLU156 + CoartemNovartisPhase 3
40
Artemether-lumefantrine (COA566)NovartisPhase 2/3
38
INE963NovartisPhase 2
35
KAE609 + SoC (Coartem) + KLU156NovartisPhase 2
35
KAF156 + Coartem + Lumefantrine Solid Dispersion FormulationNovartisPhase 2
35
INE963 + KAE609 (Cipargamin) + SoC (Coartem) + KLU156NovartisPhase 2
42
KAF156 + LUM-SDF + CoartemNovartisPhase 2
35
Co-artemetherNovartisApproved
43
Broncho-munal® + PlaceboSandoz GroupPhase 3
37
Placebo of Phenazopyridine Hydrochloride Tables, USP 200 mg + Phenazopyridine Hydrochloride Tables, USP 200 mgAmneal PharmaceuticalsPhase 3
37
Peramivir + PlaceboBioCryst PharmaceuticalsPhase 2
29
solithromycin + ceftriaxone + azithromycinAllergy TherapeuticsPhase 3
34
Sulopenem-Etzadroxil/Probenecid + CiprofloxacinIterum TherapeuticsPhase 3
30